Tyrian to Develop Second Crop DiagnostIQâ„¢ Product for Bayer CropScience AG
December 18 2008 - 8:00AM
Business Wire
Tyrian Diagnostics Limited (ASX:TDX) announced today that the
Company has agreed to commence the development of a second
point-of-need diagnostic product with Bayer CropScience AG
(�Bayer�). The product will utilise Tyrian Diagnostics� (�Tyrian�)
DiagnostIQ� test device and the test content will be provided by
Bayer. This new project follows the commencement of marketing by
Bayer of the first product generated by the collaboration,
WheatRite�, a test for analysis of wheat quality. Jenny Harry, CEO
of Tyrian Diagnostics, said �We are delighted that Bayer has
committed to development of a second innovative application for our
DiagnostIQ platform and we continue to pursue advancement of this
technology in other product areas." Tyrian expects to complete the
proof-of-concept phase of this product development programme by 2nd
quarter 2009. Bayer will fund the development costs of the project
and Tyrian would receive annual�licence fees and royalties on net
sales of a commercial product. About DiagnostIQ� DiagnostIQ� is a
point-of-need diagnostic test platform for the development of rapid
and quantitative tests. The patented technology comprises an
antibody/antigen printed membrane, a unique pre-filter device and
an incubation chamber in a vertical flow-through format. The test
is simple to use, gives rapid and accurate results, and is suitable
for use with crude samples such as whole blood, sputum, saliva, or
plant materials. The DiagnostIQ test can be used with a portable
digital reader when quantitative test results are required.
DiagnostIQ has the potential to be used as a diagnostic platform
for virtually any analyte for which antibodies or antigens are
available. The global market opportunity for such tests is very
large and the discovery of new high quality disease biomarkers is
expected to fuel further growth. About Tyrian Diagnostics Tyrian
Diagnostics (ASX:TDX) is a diagnostics company with expertise in
biomarker discovery and validation and diagnostic test development
and a core focus on respiratory and infectious diseases. In
addition, Tyrian can partner in alternative fields given its
capabilities to work across the entire spectrum of diagnostic test
development � from identification and isolation of biomarkers,
point-of-need test design, clinical development or field testing to
final product. Tyrian�s product pipeline includes: WheatRite� for
measuring wheat quality, which is partnered with Bayer CropScience
AG; and a rapid test for active tuberculosis, in collaboration with
US-based diagnostic group Becton, Dickinson and Company. Additional
information about Tyrian Diagnostics can be found at
www.tyriandx.com
Tyrian Diagnostics (ASX:TDX)
Historical Stock Chart
From Dec 2024 to Jan 2025
Tyrian Diagnostics (ASX:TDX)
Historical Stock Chart
From Jan 2024 to Jan 2025